Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes

In order to investigate the biologic significance of HLA-DR expression by human keratinocytes, we have examined the possibility that DR-positive keratinocytes become alloantigen presenting cells for resting T cells in the presence of interleukin-2. Using this system, gamma interferon-treated, DR-pos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of investigative dermatology 1987-11, Vol.89 (5), p.464-468
Hauptverfasser: Morhenn, Vera B., Nickoloff, Brian J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 468
container_issue 5
container_start_page 464
container_title Journal of investigative dermatology
container_volume 89
creator Morhenn, Vera B.
Nickoloff, Brian J.
description In order to investigate the biologic significance of HLA-DR expression by human keratinocytes, we have examined the possibility that DR-positive keratinocytes become alloantigen presenting cells for resting T cells in the presence of interleukin-2. Using this system, gamma interferon-treated, DR-positive keratinocytes stimulate the proliferation of allogeneic, resting T cells approximately 3-fold whereas non-gamma interferon-treated, DR-negative keratinocytes do not. Because a monoclonal antibody against recombinant gamma interferon inhibits this proliferation, the stimulation is dependent on pre-incubation with gamma interferon. By contrast, since the stimulation is not inhibited by a monoclonal antibody against HLA-DR, it is not clear that the stimulation is due to class II antigen expression by keratinocytes. To rule out that gamma interferon increases the expression of class I antigens, leading to stimulation of resting T cells on that basis, we determined whether gamma interferon treatment enhances class I antigen expression by keratinocytes. The lymphokine treated cells did not demonstrate more class I antigen expression than untreated keratinocytes. Thus, the observed stimulation of allogeneic, resting T cells by gamma interferon-treated keratinocytes in the presence of IL-2 is not due to increased class I antigen expression but is due to other cell surface antigen(s) induced by recombinant gamma interferon treatment. These results suggest that gamma interferon-exposed keratinocytes in the presence of interleukin-2 may augment the activation of resting T lymphocytes and, in this manner, may contribute to cutaneous inflammation.
doi_str_mv 10.1111/1523-1747.ep12460913
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_81063647</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022202X87900649</els_id><sourcerecordid>81063647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-c26ebec89924f2171e718b3794ec7387783b2eede02250b25f8546ad125b60943</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EKkvhG4DkE3AgxX_i2LkgVRW0FSshwSJxsxxnUgyJHWwHab89Drva3uqLJf_evPHMQ-glJRe0nPdUMF5RWcsLmCmrG9JS_ghtTs-P0YYQxipG2I-n6FlKvwihTS3UGTrjlMqW8A3Ktz5DHGH57XzF8LfspmU0GRL-Cik7f4dvlsl4vMPb_TT_DHZf2JsVzsEnwDngy3EMd-DB2Xf42kyTwf89B4jBV7sIxa3HnyGaYneof46eDGZM8OJ4n6Pvnz7urm6q7Zfr26vLbWW5aHJlWQMdWNW2rB4YlRQkVR2XbQ1WciWl4h0D6KFMKUjHxKBE3ZieMtGVbdT8HL0--M4x_FnKPHpyycI4Gg9hSVpR0vCmlkX49kEhZUoQxRu5SuuD1MaQUoRBz9FNJu41JXrNRa8B6DUAfZ9LKXt17LB0E_SnomMQ99ybvEQ4cdFQrjgr_MOBQ9nXXwdRJ-vAW-hdBJt1H9zDH_gH_K2mnw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1285083677</pqid></control><display><type>article</type><title>Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Morhenn, Vera B. ; Nickoloff, Brian J.</creator><creatorcontrib>Morhenn, Vera B. ; Nickoloff, Brian J.</creatorcontrib><description>In order to investigate the biologic significance of HLA-DR expression by human keratinocytes, we have examined the possibility that DR-positive keratinocytes become alloantigen presenting cells for resting T cells in the presence of interleukin-2. Using this system, gamma interferon-treated, DR-positive keratinocytes stimulate the proliferation of allogeneic, resting T cells approximately 3-fold whereas non-gamma interferon-treated, DR-negative keratinocytes do not. Because a monoclonal antibody against recombinant gamma interferon inhibits this proliferation, the stimulation is dependent on pre-incubation with gamma interferon. By contrast, since the stimulation is not inhibited by a monoclonal antibody against HLA-DR, it is not clear that the stimulation is due to class II antigen expression by keratinocytes. To rule out that gamma interferon increases the expression of class I antigens, leading to stimulation of resting T cells on that basis, we determined whether gamma interferon treatment enhances class I antigen expression by keratinocytes. The lymphokine treated cells did not demonstrate more class I antigen expression than untreated keratinocytes. Thus, the observed stimulation of allogeneic, resting T cells by gamma interferon-treated keratinocytes in the presence of IL-2 is not due to increased class I antigen expression but is due to other cell surface antigen(s) induced by recombinant gamma interferon treatment. These results suggest that gamma interferon-exposed keratinocytes in the presence of interleukin-2 may augment the activation of resting T lymphocytes and, in this manner, may contribute to cutaneous inflammation.</description><identifier>ISSN: 0022-202X</identifier><identifier>EISSN: 1523-1747</identifier><identifier>DOI: 10.1111/1523-1747.ep12460913</identifier><identifier>PMID: 3117903</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Alloantigens ; Antibodies, Monoclonal - immunology ; Cell activation ; Cell proliferation ; Cell surface ; Cells, Cultured ; Dermatology ; Epidermal Cells ; Epidermis - drug effects ; Epidermis - immunology ; gamma -Interferon ; Histocompatibility antigen HLA ; HLA-D Antigens - biosynthesis ; HLA-DR Antigens - biosynthesis ; HLA-DR Antigens - immunology ; Humans ; Interferon-gamma - pharmacology ; Interleukin 2 ; Interleukin-2 - pharmacology ; Isoantibodies - immunology ; Keratinocytes ; Lymphocyte Activation - drug effects ; Lymphocytes T ; Lymphokines ; Monoclonal antibodies ; Recombinant Proteins - pharmacology ; Stimulation, Chemical ; T-Lymphocytes - drug effects ; T-Lymphocytes - immunology</subject><ispartof>Journal of investigative dermatology, 1987-11, Vol.89 (5), p.464-468</ispartof><rights>1987 The Society for Investigative Dermatology, Inc</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-c26ebec89924f2171e718b3794ec7387783b2eede02250b25f8546ad125b60943</citedby><cites>FETCH-LOGICAL-c356t-c26ebec89924f2171e718b3794ec7387783b2eede02250b25f8546ad125b60943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3117903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morhenn, Vera B.</creatorcontrib><creatorcontrib>Nickoloff, Brian J.</creatorcontrib><title>Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes</title><title>Journal of investigative dermatology</title><addtitle>J Invest Dermatol</addtitle><description>In order to investigate the biologic significance of HLA-DR expression by human keratinocytes, we have examined the possibility that DR-positive keratinocytes become alloantigen presenting cells for resting T cells in the presence of interleukin-2. Using this system, gamma interferon-treated, DR-positive keratinocytes stimulate the proliferation of allogeneic, resting T cells approximately 3-fold whereas non-gamma interferon-treated, DR-negative keratinocytes do not. Because a monoclonal antibody against recombinant gamma interferon inhibits this proliferation, the stimulation is dependent on pre-incubation with gamma interferon. By contrast, since the stimulation is not inhibited by a monoclonal antibody against HLA-DR, it is not clear that the stimulation is due to class II antigen expression by keratinocytes. To rule out that gamma interferon increases the expression of class I antigens, leading to stimulation of resting T cells on that basis, we determined whether gamma interferon treatment enhances class I antigen expression by keratinocytes. The lymphokine treated cells did not demonstrate more class I antigen expression than untreated keratinocytes. Thus, the observed stimulation of allogeneic, resting T cells by gamma interferon-treated keratinocytes in the presence of IL-2 is not due to increased class I antigen expression but is due to other cell surface antigen(s) induced by recombinant gamma interferon treatment. These results suggest that gamma interferon-exposed keratinocytes in the presence of interleukin-2 may augment the activation of resting T lymphocytes and, in this manner, may contribute to cutaneous inflammation.</description><subject>Alloantigens</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Cell activation</subject><subject>Cell proliferation</subject><subject>Cell surface</subject><subject>Cells, Cultured</subject><subject>Dermatology</subject><subject>Epidermal Cells</subject><subject>Epidermis - drug effects</subject><subject>Epidermis - immunology</subject><subject>gamma -Interferon</subject><subject>Histocompatibility antigen HLA</subject><subject>HLA-D Antigens - biosynthesis</subject><subject>HLA-DR Antigens - biosynthesis</subject><subject>HLA-DR Antigens - immunology</subject><subject>Humans</subject><subject>Interferon-gamma - pharmacology</subject><subject>Interleukin 2</subject><subject>Interleukin-2 - pharmacology</subject><subject>Isoantibodies - immunology</subject><subject>Keratinocytes</subject><subject>Lymphocyte Activation - drug effects</subject><subject>Lymphocytes T</subject><subject>Lymphokines</subject><subject>Monoclonal antibodies</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Stimulation, Chemical</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - immunology</subject><issn>0022-202X</issn><issn>1523-1747</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EKkvhG4DkE3AgxX_i2LkgVRW0FSshwSJxsxxnUgyJHWwHab89Drva3uqLJf_evPHMQ-glJRe0nPdUMF5RWcsLmCmrG9JS_ghtTs-P0YYQxipG2I-n6FlKvwihTS3UGTrjlMqW8A3Ktz5DHGH57XzF8LfspmU0GRL-Cik7f4dvlsl4vMPb_TT_DHZf2JsVzsEnwDngy3EMd-DB2Xf42kyTwf89B4jBV7sIxa3HnyGaYneof46eDGZM8OJ4n6Pvnz7urm6q7Zfr26vLbWW5aHJlWQMdWNW2rB4YlRQkVR2XbQ1WciWl4h0D6KFMKUjHxKBE3ZieMtGVbdT8HL0--M4x_FnKPHpyycI4Gg9hSVpR0vCmlkX49kEhZUoQxRu5SuuD1MaQUoRBz9FNJu41JXrNRa8B6DUAfZ9LKXt17LB0E_SnomMQ99ybvEQ4cdFQrjgr_MOBQ9nXXwdRJ-vAW-hdBJt1H9zDH_gH_K2mnw</recordid><startdate>198711</startdate><enddate>198711</enddate><creator>Morhenn, Vera B.</creator><creator>Nickoloff, Brian J.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>198711</creationdate><title>Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes</title><author>Morhenn, Vera B. ; Nickoloff, Brian J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-c26ebec89924f2171e718b3794ec7387783b2eede02250b25f8546ad125b60943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Alloantigens</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Cell activation</topic><topic>Cell proliferation</topic><topic>Cell surface</topic><topic>Cells, Cultured</topic><topic>Dermatology</topic><topic>Epidermal Cells</topic><topic>Epidermis - drug effects</topic><topic>Epidermis - immunology</topic><topic>gamma -Interferon</topic><topic>Histocompatibility antigen HLA</topic><topic>HLA-D Antigens - biosynthesis</topic><topic>HLA-DR Antigens - biosynthesis</topic><topic>HLA-DR Antigens - immunology</topic><topic>Humans</topic><topic>Interferon-gamma - pharmacology</topic><topic>Interleukin 2</topic><topic>Interleukin-2 - pharmacology</topic><topic>Isoantibodies - immunology</topic><topic>Keratinocytes</topic><topic>Lymphocyte Activation - drug effects</topic><topic>Lymphocytes T</topic><topic>Lymphokines</topic><topic>Monoclonal antibodies</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Stimulation, Chemical</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morhenn, Vera B.</creatorcontrib><creatorcontrib>Nickoloff, Brian J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigative dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morhenn, Vera B.</au><au>Nickoloff, Brian J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes</atitle><jtitle>Journal of investigative dermatology</jtitle><addtitle>J Invest Dermatol</addtitle><date>1987-11</date><risdate>1987</risdate><volume>89</volume><issue>5</issue><spage>464</spage><epage>468</epage><pages>464-468</pages><issn>0022-202X</issn><eissn>1523-1747</eissn><abstract>In order to investigate the biologic significance of HLA-DR expression by human keratinocytes, we have examined the possibility that DR-positive keratinocytes become alloantigen presenting cells for resting T cells in the presence of interleukin-2. Using this system, gamma interferon-treated, DR-positive keratinocytes stimulate the proliferation of allogeneic, resting T cells approximately 3-fold whereas non-gamma interferon-treated, DR-negative keratinocytes do not. Because a monoclonal antibody against recombinant gamma interferon inhibits this proliferation, the stimulation is dependent on pre-incubation with gamma interferon. By contrast, since the stimulation is not inhibited by a monoclonal antibody against HLA-DR, it is not clear that the stimulation is due to class II antigen expression by keratinocytes. To rule out that gamma interferon increases the expression of class I antigens, leading to stimulation of resting T cells on that basis, we determined whether gamma interferon treatment enhances class I antigen expression by keratinocytes. The lymphokine treated cells did not demonstrate more class I antigen expression than untreated keratinocytes. Thus, the observed stimulation of allogeneic, resting T cells by gamma interferon-treated keratinocytes in the presence of IL-2 is not due to increased class I antigen expression but is due to other cell surface antigen(s) induced by recombinant gamma interferon treatment. These results suggest that gamma interferon-exposed keratinocytes in the presence of interleukin-2 may augment the activation of resting T lymphocytes and, in this manner, may contribute to cutaneous inflammation.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>3117903</pmid><doi>10.1111/1523-1747.ep12460913</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-202X
ispartof Journal of investigative dermatology, 1987-11, Vol.89 (5), p.464-468
issn 0022-202X
1523-1747
language eng
recordid cdi_proquest_miscellaneous_81063647
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Alloantigens
Antibodies, Monoclonal - immunology
Cell activation
Cell proliferation
Cell surface
Cells, Cultured
Dermatology
Epidermal Cells
Epidermis - drug effects
Epidermis - immunology
gamma -Interferon
Histocompatibility antigen HLA
HLA-D Antigens - biosynthesis
HLA-DR Antigens - biosynthesis
HLA-DR Antigens - immunology
Humans
Interferon-gamma - pharmacology
Interleukin 2
Interleukin-2 - pharmacology
Isoantibodies - immunology
Keratinocytes
Lymphocyte Activation - drug effects
Lymphocytes T
Lymphokines
Monoclonal antibodies
Recombinant Proteins - pharmacology
Stimulation, Chemical
T-Lymphocytes - drug effects
T-Lymphocytes - immunology
title Interleukin-2 Stimulates Resting Human T Lymphocytes' Response to Allogeneic, Gamma Interferon-Treated Keratinocytes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T18%3A41%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin-2%20Stimulates%20Resting%20Human%20T%20Lymphocytes'%20Response%20to%20Allogeneic,%20Gamma%20Interferon-Treated%20Keratinocytes&rft.jtitle=Journal%20of%20investigative%20dermatology&rft.au=Morhenn,%20Vera%20B.&rft.date=1987-11&rft.volume=89&rft.issue=5&rft.spage=464&rft.epage=468&rft.pages=464-468&rft.issn=0022-202X&rft.eissn=1523-1747&rft_id=info:doi/10.1111/1523-1747.ep12460913&rft_dat=%3Cproquest_cross%3E81063647%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1285083677&rft_id=info:pmid/3117903&rft_els_id=S0022202X87900649&rfr_iscdi=true